MGNet: Exploring Factors Leading to Relapse After B Cell Depletion Therapy in Patients with Myasthenia Gravis
Dec 5, 2022 ·
2m 11s
Sign up for free
Listen to this episode and many more. Enjoy the best podcasts on Spreaker!
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
New research from the Myasthenia Gravis Rare Disease Network (MGNet). This summary is based on a paper published in the journal Acta Neuropathologica Communications on October 28, 2022, titled "Reemergence...
show more
New research from the Myasthenia Gravis Rare Disease Network (MGNet). This summary is based on a paper published in the journal Acta Neuropathologica Communications on October 28, 2022, titled "Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy."
Read the paper here: https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-022-01454-0
Learn more about MGNet: https://mgnet.rarediseasesnetwork.org
show less
Read the paper here: https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-022-01454-0
Learn more about MGNet: https://mgnet.rarediseasesnetwork.org
Information
| Author | RDCRN |
| Organization | RDCRN |
| Website | - |
| Tags |
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
